Neumora Therapeutics Inc.’s stock tumbled 80% Thursday, after the clinical-stage biotech said a late-stage trial of a ...

Navacaprant is an highly selective kappa opioid receptor antagonist expected to modulate reward processing pathways and mediate depressive states.

Older adults with major depressive disorder (MDD) demonstrate distinct and riskier driving behaviors than those without MDD, ...

Major depressive disorder (MDD) is a chronic and recurrent mental condition leading to huge impacts on direct and indirect personal and public medical costs. To overcome such a serious mental ...

In this longitudinal cohort study of older drivers, adults with major depressive disorder demonstrated distinct and riskier driving behaviors than those in the control group without depression, with ...

The National Institute of Mental Health defines depression, which is also known as clinical depression or major depressive ...

The study, first of the three late-stage trials, was testing the drug, navacaprant, in patients with major depressive ...

SPL-026 is under development for the treatment of major depressive disorder (MDD). The drug candidate is a psychedelic N,N-dimethyltryptamine (DMT) based medicine. It is administered through i ...

Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...

Bipolar disorder is a mental health condition marked by large shifts in mood from mania to depression. Although bipolar disorder can be challenging to manage, many effective treatments and ...

The changing landscape of health care during COVID-19 placed focus on increasing accessibility to mental health resources other than the emergency department (ED), with potential savings of over $ ...

Nelivaptan (NB-415, SSR-149415) is under development for the treatment of depression including major depressive disorder (MDD). The drug candidate targets vasopressin receptor 1B ( (V1bR). It is ...